 HAUPPAUGE, N.Y., Nov. 13, 2020 GLOBE NEWSWIRE -- Chembio Diagnostics, Inc. Nasdaq: CEMI, a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received regulatory approval from Agência Nacional de Vigilância Sanitária ANVISA to market the DPP SARS-CoV-2 Antigen test system in Brazil. 